Yavas Ozlem, Yazici Mehmet, Eren Onder, Boruban Cem, Artac Mehmet, Genc Mine
Department of Medical Oncology, Meram Medical School, Selcuk University, Meram, Konya, Turkey.
Support Care Cancer. 2008 Sep;16(9):1011-5. doi: 10.1007/s00520-007-0400-2. Epub 2008 Feb 1.
The 5-hydroxytryptamine 3 receptor antagonists, including tropisetron, ondansetron, granisetron, and dolasetron are agents used effectively for supportive care. They are used for the prevention and treatment of chemotherapy and radiotherapy-induced emesis. Despite their overall excellent safety profile, some electrocardiographic changes related to heart rate and repolarization were reported. Ondansetron, granisetron, and dolasetron were studied on this manner. But to our knowledge, there is no information about the cardiac side effects of tropisetron. In this study, we aimed to determine the acute effects of tropisetron on ECG parameters related to repolarization, heart rate, and systemic blood pressure.
Fifty-five cancer patients who received tropisetron for the prevention of acute chemotherapy-induced nausea and vomiting were enrolled into this single center, prospective study. Standard 12-lead ECG recordings were performed at baseline and 30 min after tropisetron (5 mg given over 1 min IV bolus) administration. P wave durations and corrected QT intervals were measured; P wave dispersion and QTc dispersion were calculated.
In comparison with baseline, mean heart rate significantly decreased 30 min after administration of tropisetron. Tropisetron did not result in a significant change in P wave duration, corrected QT interval, P dispersion, and QTc dispersion.
In this study, tropisetron did not show any ventricular and atrial arrhythmogenic effect because of repolarization abnormalities. Only it may cause a slight decrease in heart rate.
5-羟色胺3受体拮抗剂，包括托烷司琼、昂丹司琼、格拉司琼和多潘立酮，是有效用于支持治疗的药物。它们用于预防和治疗化疗及放疗引起的呕吐。尽管其总体安全性良好，但有报道称出现了一些与心率和复极相关的心电图变化。昂丹司琼、格拉司琼和多潘立酮已进行过此类研究。但据我们所知，尚无关于托烷司琼心脏副作用的信息。在本研究中，我们旨在确定托烷司琼对与复极、心率和全身血压相关的心电图参数的急性影响。
55例接受托烷司琼预防急性化疗引起的恶心和呕吐的癌症患者被纳入这项单中心前瞻性研究。在基线时以及托烷司琼（5mg静脉推注1分钟给药）给药后30分钟进行标准12导联心电图记录。测量P波时限和校正QT间期；计算P波离散度和QTc离散度。
与基线相比，托烷司琼给药后30分钟平均心率显著降低。托烷司琼未导致P波时限、校正QT间期、P波离散度和QTc离散度出现显著变化。
在本研究中，托烷司琼未因复极异常而显示出任何室性和房性致心律失常作用；仅可能导致心率略有下降。
